Centene announced that it has successfully completed the previously announced divestiture of Magellan Rx to Prime Therapeutics LLC. Centene acquired Magellan Rx in January 2022 as part of its acquisition of Magellan Health.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CNC:
- CENTENE COMPLETES DIVESTITURE OF MAGELLAN RX
- Managed care company returns will be tough to keep replicating, WSJ says
- CENTENE SIGNS DEFINITIVE AGREEMENT TO DIVEST MAGELLAN SPECIALTY HEALTH
- EVOLENT HEALTH ANNOUNCES ACQUISITION OF SPECIALTY ASSET NIA AND STRATEGIC PARTNERSHIP WITH CENTENE
- CENTENE COMPLETES DIVESTITURE OF ITS SPANISH AND CENTRAL EUROPEAN BUSINESSES